SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

Mar 2, 2022

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

Feb 10, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 3, 2022

SCYNEXIS to Participate in Upcoming January Investor Conferences

Jan 6, 2022

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

Dec 22, 2021

BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients

Dec 20, 2021

European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis

Dec 15, 2021

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Dec 6, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2021

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

Dec 3, 2021